Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Desipramine · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories) |
| 2 | ACTIVE_COMPARATOR | Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.) |
| Name | Type | Description |
|---|---|---|
| Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories) | DRUG | - |
| Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.) | DRUG | - |
| Desipramine Hydrochloride 50 mg Tablets (Cord Laboratories) | DRUG | - |
| Desipramine Hydrochloride 50 mg Tablets (Merrell Dow Pharmaceuticals, Inc) | DRUG | - |
Inclusion Criteria: * No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: * Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.
Desipramine is a small molecule developed for depression, a condition within the psychiatry therapeutic area. It is being studied by Novartis AG under ticker NVS. The clinical program to date has focused on depression as the target indication, with trials conducted in healthy adult male volunteers.
Desipramine targets SLC6A2, also known as the norepinephrine transporter. It acts as an inhibitor of this target. By inhibiting SLC6A2, desipramine affects norepinephrine reuptake, which is the mechanism underlying its activity in depression.
Desipramine is developed by Novartis AG, which trades under the ticker NVS. The drug is also referenced as Desipramine Hydrochloride 100 mg Tablets and Desipramine Hydrochloride 50 mg Tablets, both associated with Cord Laboratories.
Desipramine is in Phase 1 clinical development. It is an investigational small molecule and has not been approved. Two Phase 1 trials have been completed, with no active trials currently listed. Total enrollment across the completed studies was 72 participants.
Desipramine has been studied in two completed Phase 1 trials. NCT00913822 evaluated the relative bioavailability of desipramine hydrochloride tablets, and NCT00913237 evaluated the relative bioavailability of the 50 mg tablets. Both enrolled 36 healthy male volunteers and were active-controlled, randomized studies.